New health care reforms are at the forefront of the proposed rule for 2018 by the Centers for Medicare and Medicaid Services (CMS), which said in a release it believes would work to stabilize the health insurance markets to best serve and protect patients.
Patients taking the rheumatoid arthritis drug baricitinib showed greater improvement than those taking adalimumab, sold under the brand name Humira, over the same period, Eli Lilly and Company reported recently.
The global biotechnology company Shire Plc offered its latest insights into certain lysosomal diseases through presentations, satellite symposia and booths at the recent 13th annual WORLD Symposium in San Diego, the company said.
The chairman of the House Ways and Means Committee described Dr. Tom Price as exactly the leader America needs to take over Health and Human Services following Price's Senate confirmation, the committee announced recently.
Older women who lose weight can significantly reduce their risk of endometrial cancer, the most common form of uterine cancer, a recent study indicates. The risk reduction is most pronounced among obese woman who lose weight.
The U.S. Department of Agriculture turned up its attack on salt in public schools recently, sending an outline of the second phase of its sodium-reduction programs to state agencies responsible for school meal programs. The phase is set to begin at the start of the next school year.
Duchenne muscular dystrophy research received a boost from Parent Project Muscular Dystrophy in the form of a $250,000 grant awarded to Dr. Eric Olson and the Department of Molecular Biology at the University of Texas Southwestern Medical Center.
Physicians have opposed the merger between Aetna and Humana for over a year and a half, trying to challenge the merger by giving the Department of Justice and state attorneys general evidence against the merger.
The U.S. Food and Drug Administration approved AbbVie’s IMBRUVICA for treatment of relapsed/refractory marginal zone lymphoma in patients who require systemic therapy and have received at least one prior anti-CD 20-based therapy.